John Oppenheimer

2 months ago | healio.com | Isabella Hornick |Kristen Dowd |John Oppenheimer |Sarah Rhoads

Perspective Back to Top John J. Oppenheimer, MD While it is known that mepolizumab can induce remission on therapy in a subgroup of asthmatics and there are data indicating which asthmatics are likely to respond, this study adds to our ability to optimize care, demonstrating that ACQ-5 score at 6 months was the best predictor of achieving remission at 1 year.

Sep 13, 2024 | healio.com | Richard Gawel |Kristen Dowd |John Oppenheimer

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Depemokimab has high binding affinity and potency for IL-5. Eosinophils fell by 83% and 82% with treatment in the two trials. The treatment and placebo groups had similar rates and types of adverse events.

Jul 16, 2024 | healio.com | Richard Gawel |Kristen Dowd |David B.K. Golden |John Oppenheimer

Perspective Back to Top David B.K. Golden, MDCM Physiologic patterns and manifestations of anaphylaxis differ in infants and toddlers, and they are not included in the current criteria. Also, these children cannot communicate their symptoms like older children or adults, so they cannot meet some of the criteria set for adults. Previous studies by these investigators and others have identified a range of observed symptoms and signs in infants and toddlers during allergic reactions.

Jan 17, 2024 | healio.com | Richard Gawel |Kristen Dowd |John Oppenheimer |Margitta Worm

John J. Oppenheimer, MD As pointed out by the authors, epidemiologic data regarding occupational anaphylaxis are woefully scant. The difficulty in doing such research becomes evident when one considers that the authors began with 5,851 cases with occupational information, but ultimately only 225 (3.8%) anaphylactic episodes were considered to be caused by an occupational allergen. In light of these small numbers, it is difficult to read too much into these findings.

Sep 13, 2023 | healio.com | Richard Gawel |Kristen Dowd |Juanita Mora |John Oppenheimer

Source/Disclosures Disclosures: Oppenheimer reports adjudication and data and safety monitoring board participation for AstraZeneca, GSK and Sanofi/Regeneron and consultant roles with Aimmune, Amgen, Aquestive, ARS, GSK and Teva. Please see the paper for all other authors’ relevant financial disclosures. You've successfully added Allergy/Asthma: Asthma and Respiratory Disorders to your alerts. You will receive an email when new content is published.